ClinicalTrials.gg
Not yet recruitingNCT06531694EMBODYUpdated Oct 16, 2026

EMBodied psychOsocial Impacts of Weight Stigma During Pregnancy (EMBODY): A Prospective Cohort Study

An observational study in Weight Stigma, Pregnancy Outcomes and Overweight and Obesity, sponsored by Monash University. Not yet recruiting at 2 sites in Australia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Primary conditionObesityRegistry: Weight PrejudiceReclassifiedWhy we changed it
Registry
Weight Prejudice — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. Weight Prejudice is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Monash University · Observational

Updated Oct 16, 2026First site in AustraliaStart date moved+5 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this prospective cohort study is to investigate the contribution of stigma and discrimination due to body size to adverse pregnancy outcomes. We also aim to explore the role of psychological and social factors in this relationship. The specific objectives of this study are:

Objective 1: Explore weight stigma as a mediator of the association between BMI ≥30 kg/m2 and adverse pregnancy outcomes.

Objective 2: Explore confounding factors not previously considered such as weight cycling, trauma, eating disorders, and internalised weight bias as mediators in the relationship between obesity and adverse pregnancy outcomes.

Consenting participants will complete an online survey question at 20-22 weeks' gestation, 29-31 weeks' gestation, 35-37 weeks' gestation, and 6 weeks postpartum. Additional data will be extracted from their EMR.

Read the detailed description

The specific research questions for each objective are:

Objective 1 RQ1.1: Does weight stigma experienced during pregnancy in a healthcare setting reported up to 34 weeks gestation mediate the association between pre-pregnancy obesity (BMI ≥30) and gestational diabetes mellitis (GDM) (primary outcome)?

RQ1.2: Does weight stigma experienced during pregnancy in a healthcare setting reported up to 34 weeks gestation mediate the association between pre-pregnancy obesity (BMI ≥30) and (i) induction of labour; (iv) mode of birth; (ii) gestational hypertension (any); (iii) infant birth weight; and (iv) establishment of breastfeeding by 6 weeks postpartum (secondary outcomes)?

Objective 2:

RQ2.1: Do weight cycling, history of trauma, history of eating disorders, and internalised weight bias explain any of the variance in the mediation relationships described above? Methods 800 participants will be recruited through the Adelaide Women's and Children's Hospital and Royal Brisbane and Women's Hospital. While waiting for their booking appointment, women will be approached by the researcher or research midwife and asked if they would like to hear about the study. Women who agree will be assessed for eligibility and provided a brief explanation of the research. Eligible women will be given the study information sheet and counselling about their potential participation by the researcher or research midwife. A brief video containing information about study objectives and participation may also be displayed in the waiting areas or available to women to access and watch. Interested women will be invited to scan a QR code to express their interest and provide consent via an online version of the consent form. Consenting participants will complete a online survey question at 20-20 weeks' gestation, 29-31 weeks' gestation, 35-7 weeks' gestation, and 6 weeks postpartum. Additional data will be extracted from their EMR. Information will be collected. The questionnaire will be completed online via the REDCap. Each time, participants will be invited to complete the questionnaire within the next two weeks. At each time point, women who do not complete the questionnaire within the two-week period will be followed up a maximum of three times via email or text message (reminders at 1 week, 11 days, and 14 days post initial survey request).

The survey will collect data on primary and secondary outcomes, as well as independent and potential confounding variables. The primary outcome is gestational diabetes mellitus (GDM). Secondary outcomes include induction of labour, mode of birth, gestational age at birth, infant admission to the neonatal unit, hypertensive disorders of pregnancy (HDP), infant birth weight and length, and infant feeding practices, including the establishment of exclusive breastfeeding.

Independent and potential confounding variables include BMI, experiences and sources of weight stigma, weight loss and weight cycling, medication, supplement, or herbal/homeopathic use, history of trauma, eating disorders or disordered eating, Midwifery Continuity of Care (CoC) model, women's experiences of respectful maternity care, mental health, self-esteem, body image, and labour pain relief measures.

Data will be presented as mean (standard deviation) or median (25th-75th percentile) for continuous variables and as count (percentage) for categorical variables. Comparisons of women's profiles across the outcomes will be performed using Fisher's exact test and t-test and Mann-Whitney tests, as appropriate. For the binary outcomes, univariable and multivariable logistic regression analyses will be conducted to estimate unadjusted and adjusted odds ratios (ORs), respectively. The conceptual models, including the mediation effect of the weight stigma on obesity - adverse outcomes relationships, will be assessed in the structural equation modelling framework

02

Conditions studied

  • Weight Stigma
  • Pregnancy Outcomes
  • Overweight and Obesity

Browse trials for

Keywords

  • Prenatal care
  • Healthcare
  • maternity care
03

In context

Obesity Reclassified

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 800 is above the median of 114 across 2,154 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Monash University is the lead sponsor of 83 studies on the registry; 22 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Weight Prejudice. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be pregnant women who are at least 18 years old with a singleton pregnancy, and who are booked in to give birth at Adelaide Women's and Children's Hospital or Royal Women's and Children's Brisbane. At baseline, women must be between 10 and 22 weeks' gestation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant between 10-22 weeks' gestation
  • Greater or equal than 18 years of age
  • Booked to give birth at Adelaide Women's and Children's Hospital or Royal Women's and Children's Brisbane
  • Access to the Internet to complete the survey
  • Consents to the extraction of hospital electronic medical record data about the woman and relevant to the study.
  • Can complete consent and study procedures in English

Exclusion criteria

Exclusion Criteria:

  • Pregnant with multiple gestation
  • Insufficient English language skills to consent and complete the questionnaires.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Proportion of women diagnosed with gestational diabetes mellitus by 35-37 weeks gestation

    Measuring the number of women reporting a diagnosis of gestational diabetes mellitus by 35-37 weeks gestation as assessed via self-reported measures and chart review.

    Time frame: 35-37 weeks

Secondary outcomes

  1. Proportion of women experiencing induction of labour

    Identifying whether the woman's labour was spontaneous or induced measured via a self-reported questionnaire.

    Time frame: 6 weeks postpartum

  2. Proportion of women reporting each mode of birth (i.e., vaginal birth, caesarean section, assisted vaginal birth, or other)

    Identifying the mode of birth assessed via a self-reported questionnaire. Options are: vaginal birth, caesarean section, assisted vaginal birth (e.g., with forceps), or other.

    Time frame: 6 weeks postpartum

  3. Proportion of women who reported experiencing gestational hypertension in their most recent pregnancy

    Identifying the proportion of women who reported a diagnosis of gestational hypertension during their most recent pregnancy via a self-reported questionnaire.

    Time frame: 6 weeks postpartum

  4. Infant birth weight (in grams) reported by mothers for their most recent infant

    Infant birth weight (in grams) reported by mothers based on their most recent baby's birth certificate or hospital discharge summary information.

    Time frame: 6 weeks postpartum

  5. Proportion of women currently breastfeeding their infant reported by mothers at 6-weeks postpartum

    The proportion of women currently breastfeeding their infant (yes/no) reported by mothers at 6-weeks postpartum

    Time frame: 6 weeks postpartum

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — A copy of the raw, fully de-identified prospective survey dataset, along with the corresponding data dictionary and R/Stata analysis scripts, will be uploaded to an open-access repository (such as Monash Bridges / Figshare) upon peer-reviewed publication of primary outcomes. Although primary de-identified survey data will be made available via open-access repositories upon publication, access to the broader, linked longitudinal dataset (including extracted EMR variables and detailed scale sub-scores) is managed under a Managed Access Framework to protect participant confidentiality and ensure responsible secondary data use.

Supporting information: Analytic code

Time frame: After the primary study findings are published and will end based on Monash University's data retention policy

Access criteria: Before submitting a formal application, interested applicants must ensure they meet the baseline eligibility criteria (recognised affiliation, aligning scope) Applicants must submit a completed EMBODY Data Access Request Form to the Lead Investigator (Dr. Briony Hill, Monash University, SPHPM). The application package must include: Project Proposal (Max 2-3 pages); Ethics Clearance; Data Security \& Storage Plan Applications undergo a two-tier review process Upon proposal approval, a formal Data Use Agreement (DUA) must be executed between Monash University and the applicant's host institution. Once the DUA is fully executed, a de-identified, minimal dataset containing only the variables explicitly approved for the project will be shared securely via encrypted, password-protected channels.

Data sharing details ↗ · bridges.monash.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Dec 2027, 10 months later.

Of 791 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 10 months is below that.

Counting every sponsor, half of 836 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Jun 2026 → Feb 2027 and completion Dec 2028 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2024
First posted
Aug 1, 2024
StartEst.
Feb 2027was Jun 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027was Dec 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in Australia
Show 2 added (2 Australia)
  • The Royal Brisbane and Women's Hospital · Brisbane, Australia
  • The Women's and Children's Hospital · Adelaide, Australia
Oct 16, 2026
Start date
Jun 2026→Feb 2027
Oct 16, 2026
Study completion
Dec 2028→Dec 2027
Oct 16, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Ability to read and understand EnglishNow Can complete consent and study procedures in English
Oct 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportion of women diagnosed with gestational diabetes mellitismellitus by 3435-37 weeks gestationTime frame: 34 weeks → 35-37 weeks
Oct 16, 2026
Title
Unravelling the InterplayEMBodied psychOsocial Impacts of Weight Stigma andDuring Pregnancy Outcomes(EMBODY): A Prospective Cohort Study
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    2 sites added — first site in Australia
    Show 2 added (2 Australia)
    • The Royal Brisbane and Women's Hospital · Brisbane, Australia
    • The Women's and Children's Hospital · Adelaide, Australia
    Start date Jun 2026→Feb 2027
    Study completion Dec 2028→Dec 2027
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Ability to read and understand EnglishNow Can complete consent and study procedures in English
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportion of women diagnosed with gestational diabetes mellitismellitus by 3435-37 weeks gestationTime frame: 34 weeks → 35-37 weeks
    Title Unravelling the InterplayEMBodied psychOsocial Impacts of Weight Stigma andDuring Pregnancy Outcomes(EMBODY): A Prospective Cohort Study
    + 5 other changes: responsible party, oversight details, description, conditions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06531694
Lead sponsor
Monash University
Collaborators
Women's and Children's Hospital, Australia, Royal Brisbane and Women's Hospital
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Feb 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Briony Hill, PhD
Contact
briony.hill@monash.edu
+61421012283
Megan Mitchell, PhD
Contact
megan.mitchell@adelaide.edu.au
Briony Hill, PhD
principal investigator · Monash University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion